- Kuria's Chief Executive Officer Dr. Keith Ward to discuss preclinical proof-of-concept data in dry AMD and Kuria's development plans...

- Expands development pipeline with planned Phase 2 clinical trial for dry AMD Kuria Therapeutics, a pharmaceutical company developing a...

- Chief Executive Officer Dr. Keith Ward will discuss Kuria's development of novel Nrf2 activators to power sight Kuria Therapeutics, a...

Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease LITTLE ROCK,...

SCOHIA PHARMA and Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator KANAGAWA, Japan & LITTLE ROCK,...

Kuria Therapeutics Closes Initial Fundraising Round to Develop Novel Nrf2 Activator - Funds to support ongoing preclinical development...

Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2...